TTM 2025

Apeximmune Therapeutics is a biotechnology company focused on developing next-generation immunotherapies for cancer and autoimmune diseases. The company leverages its proprietary discovery and validation platform to target novel immune escape mechanisms, specifically focusing on the newly identified checkpoint protein AIM-103. Its lead candidate, AI-306, is a first-in-class antagonist monoclonal antibody designed to reinvigorate anti-tumor T cell immunity in aggressive gastrointestinal cancers. Additionally, Apeximmune is developing bispecific macrophage engagers to further enhance the immune response against high-mortality tumors. The company recently secured Series A funding to accelerate its lead programs toward clinical validation.